Balanced news tone
News Sentiment
INM sentiment intelligence
InMed Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
45 relevant articles
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
+5.1% over one week, +8.6% over four weeks, trend active, and below fair value.
InMed Pharmaceuticals(INM) Stock Options Chain | Quotes & News
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
77/100 classification
One-week reaction
5.1%
Price confirming higher
Trend fit
Trend active
8.6% over four weeks
Fair value
-67.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
8
Neutral
35
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
InMed Pharmaceuticals(INM) Stock Options Chain | Quotes & News
This article provides access to the stock options chain, quotes, and news for InMed Pharmaceuticals (INM). While no specific content beyond "Document" was present in the input, the title indicates it serves as a portal for financial information related to the company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 15:40
- Source
- Moomoo
The Motley Fool
Direct company coverage
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 01:20
- Source
- The Motley Fool
TradingView
Direct company coverage
InMed Pharmaceuticals Updates Mentari Merger Terms, Adding PIPE Option and Confirming Tax Reorganization
InMed Pharmaceuticals has updated its merger agreement with Mentari Therapeutics to clarify closing steps, introduce a Company PIPE Amendment for potential pre-closing financing, and confirm that the combined mergers are intended to qualify as a tax-free reorganization under Sect
- Tone
- Positive 65/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 20:08
- Source
- TradingView
Stock Titan
Direct company coverage
InMed Pharmaceuticals (NASDAQ: INM) clarifies Mentari merger structure and targets Q4 2026 closing
InMed Pharmaceuticals (NASDAQ: INM) has clarified the structure of its all-stock merger with Mentari Therapeutics through an amendment to their original agreement. The revision outlines the sequencing of steps, including InMed changing its name to "Mentari Therapeutics, Inc." and
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 20:08
- Source
- Stock Titan
Stock Titan
Direct company coverage
InMed Pharmaceuticals (Nasdaq: INM) refines structure of planned Mentari merger
InMed Pharmaceuticals has refined the structure of its planned merger with Mentari Therapeutics through an amendment to their original agreement. Key changes include clarifying the sequence of corporate steps like a name change to "Mentari Therapeutics, Inc." and redomiciliation
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 20:08
- Source
- Stock Titan
TradingView
Direct company coverage
Enterprise value to EBIT forward of InMed Pharmaceuticals Inc. – NASDAQ:INM
This article focuses solely on the "Enterprise value to EBIT forward" metric for InMed Pharmaceuticals Inc. (NASDAQ: INM). It presents a single financial value for a specified period without further analysis or context. The content appears to be a stub or a data point from a larg
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 04:39
- Source
- TradingView
TMX Newsfile
Direct company coverage
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
InMed Pharmaceuticals announced an amendment to its merger agreement with Mentari Therapeutics for an all-stock transaction. The amendment clarifies transaction sequencing, the impact of pre-closing financing on the exchange ratio, and the intended tax treatment. InMed also filed
- Tone
- Positive 68/100
- Event
- Deals and strategy
- Published
- 07 Jul 2026 16:39
- Source
- TMX Newsfile
Moomoo
Direct company coverage
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics
InMed Pharmaceuticals has amended its previously announced definitive agreement with Mentari Therapeutics. The amendment primarily involves changing the upfront payment from USD $2.5 million cash to USD $5 million in shares of Mentari Therapeutics. The agreement still includes po
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Jul 2026 16:39
- Source
- Moomoo
Stock Titan
Direct company coverage
InMed adjusts Mentari merger terms, files SEC S-4 for vote
InMed Pharmaceuticals announced an amendment to its all-stock merger agreement with Mentari Therapeutics and the filing of a Form S-4 registration statement with the SEC. The amendment clarifies transaction sequencing, the impact of pre-closing financing on the exchange ratio, an
- Tone
- Negative 39/100
- Event
- Deals and strategy
- Published
- 06 Jul 2026 22:09
- Source
- Stock Titan
Moomoo
Direct company coverage
InMed Pharmaceuticals และ Mentari Therapeutics ประกาศแก้ไขข้อตกลงการควบรวมกิจการ พร้อมยื่นแบบแสดงรายการข้อมูลการจดทะเบียน (Registration Statement) ตามแบบ Form S-4
InMed Pharmaceuticals และ Mentari Therapeutics ได้ประกาศแก้ไขข้อตกลงการควบรวมกิจการครั้งประวัติศาสตร์ โดย InMed จะเข้าซื้อ Mentari ทั้งหมดผ่านการแลกเปลี่ยนหุ้น การแก้ไขข้อตกลงได้ปรับอัตราส่วนการแลกเปลี่ยนหุ้นเป็น 0.052605 หุ้นสามัญของ InMed สำหรับทุกหุ้นสามัญของ Mentari และรวมเงื
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 06 Jul 2026 04:41
- Source
- Moomoo
Finviz
Direct company coverage
INM - InMed Pharmaceuticals Inc Forecast, Target Price
This article provides a detailed financial overview and forecast for InMed Pharmaceuticals Inc (INM). It includes key financial metrics such as market cap, income, sales, various ratios, and performance indicators. The stock closed at $1.56, with analysts giving it a "strong buy"
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 04 Jul 2026 03:39
- Source
- Finviz
Stock Titan
Direct company coverage
Vivo Opportunity increases InMed (INM) stake with open-market share buys
Investment entities affiliated with Vivo Opportunity have increased their stake in InMed Pharmaceuticals Inc. (INM) through a series of open-market share purchases. Between June 30 and July 2, 2026, Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Fund Holdings, L.P. acqui
- Tone
- Positive 67/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 23:14
- Source
- Stock Titan
Stock Titan
Direct company coverage
InMed (INM) to merge with Mentari after $290M financing; Exchange ~2.0606
InMed Pharmaceuticals Inc. (INM) is set to merge with Mentari Therapeutics, Inc. following a preliminary proxy statement/prospectus filing on Form S-4. The merger involves an estimated exchange ratio of approximately 2.0606 InMed Common Shares per share of Mentari Common Stock, a
- Tone
- Positive 63/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 20:14
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of InMed Pharmaceuticals Inc. – NASDAQ:INM
This article provides financial information for InMed Pharmaceuticals Inc. (NASDAQ: INM), specifically focusing on its price-to-earnings forward metric. The content appears to be a stub or a placeholder, as no specific values or analytical data are presented. It primarily lists t
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 16:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of InMed Pharmaceuticals Inc. – NASDAQ:INM
This article provides a brief overview of the "Price to sales forward" metric for InMed Pharmaceuticals Inc. (NASDAQ:INM) on TradingView. It indicates that the market was closed with no trades at the time of publication. The content appears to be a data point or a snapshot from a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 05:39
- Source
- TradingView
Finviz
Direct company coverage
INM - InMed Pharmaceuticals Inc Short Interest
This article provides a detailed overview of InMed Pharmaceuticals Inc. (INM) short interest and various financial metrics. It includes stock performance, valuation ratios, profitability, and institutional/insider ownership data, along with key trading statistics.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 02:40
- Source
- Finviz
TradingView
Direct company coverage
InMed Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:INM)
This article provides an overview of InMed Pharmaceuticals Inc. (NASDAQ: INM), including its stock performance, financial data, and future estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:10
- Source
- TradingView
TradingKey
Direct company coverage
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of InMed Pharmaceuticals Inc (INM), detailing its price momentum score of 2.73 and its ranking within the Biotechnology & Medical Research industry. It identifies current support and resistance levels for the stock, suggesting it is suit
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 22 Jun 2026 10:11
- Source
- TradingKey
TradingView
Direct company coverage
InMed Pharmaceuticals Inc. Cash Flow – DUS:MWG
This article provides financial data for InMed Pharmaceuticals Inc. (DUS:MWG), focusing on its cash flow activities. It highlights that the free cash flow for Q3 2026 was -1.52 million EUR, and for 2025, both free cash flow and operating cash flow were -6.59 million EUR. The data
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 20 Jun 2026 17:09
- Source
- TradingView
TradingView
Direct company coverage
Basic earnings per share (basic EPS) of InMed Pharmaceuticals Inc. – DUS:MWG
The article provides a financial overview of InMed Pharmaceuticals Inc. (DUS:MWG) on TradingView, specifically focusing on its basic earnings per share (basic EPS). It indicates that the market for this stock is currently closed with no trades recorded.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 09:39
- Source
- TradingView
TradingView
Direct company coverage
Dilution adjustment of InMed Pharmaceuticals Inc. – DUS:MWG
This article reports on a dilution adjustment for InMed Pharmaceuticals Inc. trading under the symbol MWG on the Dusseldorf Stock Exchange. It appears to be a financial notification published by TradingView, indicating that specific financial data providers were used for the info
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 18 Jun 2026 22:10
- Source
- TradingView
TradingView
Direct company coverage
Current ratio of InMed Pharmaceuticals Inc. – DUS:MWG
This article focuses on the current ratio of InMed Pharmaceuticals Inc., traded on the Dusseldorf Stock Exchange under the symbol MWG. It provides a financial overview, highlighting the stock's market status and referencing data from ICE Data Services and FactSet. The text is pri
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 17:09
- Source
- TradingView
TradingView
Direct company coverage
MWG Stock Price and Chart — DUS:MWG
This article provides a detailed overview of InMed Pharmaceuticals Inc. (MWG) stock traded on the Dusseldorf Stock Exchange. It includes key financial statistics, company information, upcoming earnings dates, and insights from various TradingView users regarding potential stock m
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 16:09
- Source
- TradingView
TradingKey
Direct company coverage
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article for InMed Pharmaceuticals Inc (INM) on TradingKey discusses the company's revenue breakdown. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides an overview o
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of InMed Pharmaceuticals Inc (INM), listing major shareholders and their respective proportions. It also provides institutional shareholding data over several quarters, including the number of institutions, shares held, and changes i
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
InMed Pharmaceuticals Inc (INM) Valuation: PE, PB & Fair Value Analysis
InMed Pharmaceuticals Inc (INM) currently holds a valuation score of 9.24, placing it 48th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.70, significantly below its recent high and above its recent low. Key valuation metrics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:40
- Source
- TradingKey
TradingKey
Direct company coverage
InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of InMed Pharmaceuticals Inc.'s (INM) financial health, ranking it 167 out of 388 in the Biotechnology & Medical Research industry with a financial score of 7.01. While its financial status is robust, the company's operating efficiency is noted a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:40
- Source
- TradingKey
Stock Titan
Direct company coverage
Vivo Opportunity funds disclose major InMed (INM) insider share holdings
InMed Pharmaceuticals Inc. (INM) has reported initial insider holdings for several Vivo Opportunity investment entities through a Form 3 filing. Vivo Opportunity Cayman Fund, L.P. now indirectly holds 49,679 common shares, while Vivo Opportunity Fund Holdings, L.P. indirectly hol
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jun 2026 11:39
- Source
- Stock Titan
The Globe and Mail
Direct company coverage
InMed Pharmaceuticals Regains Nasdaq Listing Compliance Status
InMed Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement. The company's stock had traded below $1.00 for 30 consecutive business days, but it subsequently closed at or above $1.00 for 10 straight days, confirming its continued listing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:39
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Vivo Opportunity entities (INM) add 249,227 InMed shares in open-market buys
Entities associated with Vivo Opportunity have acquired a combined 249,227 common shares of InMed Pharmaceuticals (INM) through open-market purchases between May 20 and June 8, 2026. The shares were bought at prices generally ranging from $1.42 to $1.75 per share. This indicates
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jun 2026 02:08
- Source
- Stock Titan